NCT02934204 Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Status UNKNOWN Phase PHASE2
NCT02928575 Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma Status UNKNOWN Phase PHASE2
NCT02898012 Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status Status COMPLETED Phase PHASE2
NCT02836028 A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer Status WITHDRAWN Phase PHASE2
NCT02831179 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Status WITHDRAWN Phase PHASE1
NCT02813135 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT02805179 A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma Status COMPLETED Phase PHASE2
NCT02799238 Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma Status COMPLETED Phase PHASE2
NCT02772107 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Status UNKNOWN Phase PHASE2/PHASE3
NCT02770378 A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma Status COMPLETED Phase PHASE1/PHASE2
NCT02766270 CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas Status UNKNOWN Phase EARLY_PHASE1
NCT02761070 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02715609 Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Status COMPLETED Phase PHASE1/PHASE2
NCT02689336 Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Status WITHDRAWN Phase PHASE2
NCT02685605 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02681705 Radiation Therapy and Combination Chemotherapy for Medulloblastoma Status UNKNOWN Phase PHASE2
NCT02672241 Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children Status UNKNOWN Phase PHASE2
NCT02667587 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Status COMPLETED Phase PHASE3
NCT02663440 Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme Status UNKNOWN Phase PHASE2